An inhibitor of the PLA2 activity of Prdx6
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MJ33 (lithium salt)

Item No. 90001844

Technical Information
Formal Name
phosphoric acid, mono[1-[(hexadecyloxy)methyl]-2-(2,2,2-trifluoroethoxy)ethyl] monomethyl ester, monolithium salt
CAS Number
1007476-63-2
Molecular Formula
C22H43F3O6P • Li
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 0.5 mg/mlDMSO: 0.25 mg/mlEthanol: 2 mg/mlEthanol:PBS(pH 7.2) (1:1): 0.5 mg/ml
SMILES
O=P(OC)([O-])OC(COCC(F)(F)F)COCCCCCCCCCCCCCCCC.[Li+]
InChi Code
InChI=1S/C22H44F3O6P.Li/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-29-18-21(31-32(26,27)28-2)19-30-20-22(23,24)25;/h21H,3-20H2,1-2H3,(H,26,27);/q;+1/p-1
InChi Key
GDLMLQJISATCEL-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    MJ33 is a selective, reversible inhibitor of the acidic, calcium-independent (ai)PLA2 activity of Prdx6, with optimal inhibition achieved at an MJ33 concentration of 3 mol%.1,2,3 It blocks the degradation of DPPC in both whole lung and isolated alveolar type II epithelial cells.4 MJ33 has been used to examine the role of Prdx6 PLA2 activity in the activation of type 2 NADPH oxidase and in the regulation of Prdx6 PLA2 activity by phosphorylation.5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fisher, A.B., and Dodia, C. Role of phospholipase A2 enzymes in degradation of dipalmitoylphosphatidylcholine by granular pneumocytes. J. Lipid Res. 37, 1057-1064 (1996).

    2. Kim, T.S., Sundaresh, C.S., Feinstein, S.I., et alIdentification of a human cDNA clone for lysosomal type Ca2+-independent phospholipase A2 and properties of the expressed protein. The Journal of Biological Chemisty 272, 2542-2550 (1997).

    3. Fisher, A.B., Dodia, C., Chander, A., et alA competitive inhibitor of phospholipase A2 decreases surfactant phosphatidylcholine degradation by the rat lung. Biochem. J. 288(Pt 2), 407-411 (1992).

    4. Fisher, A.B., Dodia, C., Feinstein, S.I., et alAltered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J. Lipid Res. 46(6), 1248-1256 (2005).

    5. Lee, I., Dodia, C., Chatterjee, S., et alProtection against LPS-induced acute lung injury by a mechanism-based inhibitor of NADPH oxidase (type 2). Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L635-L644 (2014).

    6. Wu, Y., Feinstein, S.I., Manevich, Y., et alMitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A2 activity. Biochem. 419(3), 669-679 (2009).